I strongly believe that phase II will be awarded to Nova4 Feb 2021 09:22
Under the terms of the contract, which is in two phases, Primerdesign will supply its products to
the DHSC for up to six months. Phase one has an initial fixed term of 14 weeks with the potential
to extend supply by a further 10 weeks. This first phase of the contract will involve the immediate
deployment of 300 PCR instruments, related kits and support services with a minimum value of
£150 million for the first 14 weeks. Based on this initial period, a further £100 million of revenue
could be expected for the subsequent 10 weeks, however volumes can be varied up or down
subject to certain notice criteria given by the DHSC.
The second phase of the contract, which is optional by the DHSC, allows for the provision of up
to 700 additional PCR instruments, related kits and support services, as well as additional COVID19 products from the Company’s portfolio where required. Depending upon the uptake, phase
two of the contract could generate considerably more sales than the first phase.
The intended use of the contract is for Novacyt to support the urgent requirement for COVID-19
testing of patients in the NHS. In addition to the provision of products, the Company will also
provide training and maintenance services for the q16 and q32 instrument platforms.
Novacyt has the capacity to meet the demand of both phases of this new contract, as well as to
continue to build its sales across international markets.